Search results
Results from the WOW.Com Content Network
US FDA mandates label updates on CAR-T cancer therapies. April 18, 2024 at 6:39 PM (Reuters) - The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology ...
FDA approval for children aged 6–11 was added in January 2021, after a third clinical trial was completed. [33] In 2023, approval was extended to children 2–5. [34] The US Food and Drug Administration (FDA) granted the application priority review, in addition to fast track, breakthrough therapy, and orphan drug designations.
Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.
Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic HRPC. [ 11 ] [ 12 ] [ 2 ] [ 13 ] [ 1 ] Shortly afterward, sipuleucel-T was added to the compendium of cancer treatments published by the National Comprehensive Cancer Network (NCCN) as a "category ...
FDA's advisory panel meet followed the agency's staff on Friday noting the lack of signs of reduced deaths or hospitalizations in patients who received the implant compared with those on medical ...
In the age of COVID-19, cancer hospitals like Memorial Sloan Kettering have been forced to reimagine how to care for patients like 27-year-old Eliza Paris. 'I hit the trifecta': She was battling ...
The first issue of Clinical Cancer Research was published in January 1995. [2] By 1 December 1994, 128 manuscripts had been submitted for publication by investigators representing a variety of clinical and laboratory disciplines not only from the United States but also from the international research community. In 1998, the number of ...
The approval allows the use of the cancer drug, Rybrevant, in combination with J&J's existing drug, lazertinib, as a first-line treatment for non-small cell lung cancer (NSCLC) patients with a ...